NCT06830629

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: Maze Therapeutics · Industry
• Sex: All
• Age: 18 Years – 68 Years
• Healthy volunteers: Not accepted

Summary

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Detailed description

An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.

Conditions

• Proteinuric Kidney Disease

Interventions

Type	Name	Description
DRUG	MZE829	Capsules for oral administration

Timeline

• Start date: 2025-02-05
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-02-17
• Last updated: 2026-04-17

Locations

81 sites across 3 countries: United States, France, United Kingdom

Regulatory

• FDA-regulated drug study